Anti-Cbl-c Antibody

Primary Antibodies

52456 MW

Polyclonal

ELISA: 1:10, 000 - 1:50, 000
IHC: 1:500 - 1:3, 000
IP: User optimized
WB: 1:500 - 1:3, 000

E3 ubiquitin-protein ligase CBL-C

This affinity-purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to the C-Terminal portion of Human Cbl-c.

This affinity purified antibody is directed against human Cbl-c protein. The product was affinity purified from monospecific antiserum by immunoaffinity purification. A BLAST analysis was used to suggest that this antibody would react with Cbl-c from human and chimpanzee sources. Expect partial reactivity against mouse and rat sources of Cbl-c as ~83% sequence homology is on record for the immunogen sequence. Reactivity with Cbl-c from other sources has not been determined. No reactivity is expected with Cbl-a or Cbl-b.

Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Functionally coupled with the E2 ubiquitin-protein ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal transduction; upon EGF activation, ubiquitinates EGFR. Isoform 1, but not isoform 2, inhibits EGF stimulated MAPK1 activation. Promotes ubiquitination of SRC phosphorylated at 'Tyr-419'. In collaboration with CD2AP may act as regulatory checkpoint for Ret signaling by modulating the rate of RET degradation after ligand activation; CD2AP converts it from an inhibitor to a promoter of RET degradation; the function limits the potency of GDNF on neuronal survival.

Boster Bio Anti-Cbl-c Antibody (Catalog # A03693). Tested in ELISA, IHC, IP, WB applications. This antibody reacts with Human.